Pfizer Inc.(NYSE:PFE) Edges Down Following Antitrust Lawsuit – (PFE, MRK, ABT, GSK, WAG, KR, SWY, SVU)

  on Jul 06,2012 Posted in Business News ,Featured
 
Share |
We're on   

Pfizer Inc. (NYSE:PFE) edged down in the last session as five major U.S. retailers filed an antitrust lawsuit against Pfizer and India’s Ranbaxy Laboratories Ltd on Thursday, alleging both companies planned to setback sales of generic versions of Lipitor, the best-selling drug in history.

The court case was filed in federal court in Trenton, New Jersey by Walgreen Company (NYSE:WAG), The Kroger Co. (NYSE:KR), Safeway Inc. (NYSE:SWY), SUPERVALU INC. (NYSE:SVU) and HEB Grocery Co. They charged the defendants of working on an overarching anticompetitive scheme to keep generic versions of the cholesterol drug out of the market until November 30, 2011, 20 months following the original patent expiration.

Pfizer Inc’s (NYSE:PFE) total value after the recent close was $169.76 billion and the enterprise value according to yahoo data was $186.44 billion. The previous 12 month price to sales ratio was 2.56. The company showed 12.54% as a profit margin in the last twelve months and an operating margin at 18.39%. Return on equity was 9.56% for the last twelve months. Return on assets was 4.37%.

The total value of Merck & Co., Inc (NYSE:MRK) after the latest trading session was $126.62 billion and their enterprise value was $129.21 billion. The prior 52 week price to sales ratio was 2.63. The company recorded a profit margin of 14.71% for the prior 12 months and had an operating margin of 16.83%. Return on equity for this stock was 12.73% while return on assets appeared at 6.71%.

Abbott Laboratories (NYSE:ABT) market capitalization after the most recent trading session was $101.88 billion and the enterprise value was $109.00 billion. Price to sales ratio for the prior 52 weeks was 2.59.

Taking a look at another competitor, the total value of GlaxoSmithKline plc (ADR) (NYSE:GSK) in the stock market was $114.15 billion and the takeover value of the company was $127.99 billion. The last twelve month price to sales ratio for the company was 2.65. It had a 19.18% as profit margin in the last twelve months and an operating margin at 28.45%. Return on assets was 12.63%.

 



 

Leave a Reply